Masoud H. Manjili

Immunotherapy of cancer using heat shock proteins.

Development of a recombinant HSP110-HER-2/neu vaccine using the chaperoning properties of HSP110.

Hsp110 over-expression increases the immunogenicity of the murine CT26 colon tumor.

Targeted immunotherapy using reconstituted chaperone complexes of heat shock protein 110 and melanoma-associated antigen gp100.

HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.

Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins.

Cancer immunotherapy and heat-shock proteins: promises and challenges.

Heat shock proteins HSP70 and GP96: structural insights.

Heat shock proteins and scavenger receptors: role in adaptive immune responses.

HSP110 induces "danger signals" upon interaction with antigen presenting cells and mouse mammary carcinoma.

Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals".

Chaperoning function of stress protein grp170, a member of the hsp70 superfamily, is responsible for its immunoadjuvant activity.

Immunoadjuvant chaperone, GRP170, induces 'danger signals' upon interaction with dendritic cells.

Comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma".

Heat shock proteins as vaccine adjuvants in infections and cancer.

HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses.

Come forth 1E10 anti-idiotype vaccine: delivering the promise to immunotherapy of small cell lung cancer.

Tumor immunoediting and immunosculpting pathways to cancer progression.

Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design.

Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis.

Does HER-2/neu antigen loss in metastatic breast tumors occur under immune pressure?

Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.

Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.

Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.

IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.

Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function.

GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells.

Tumour secreted grp170 chaperones full-length protein substrates and induces an adaptive anti-tumour immune response in vivo.

CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer.

Adoptive cell therapy of prostate cancer using female mice-derived T cells that react with prostate antigens.

Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.

Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure.

A signature of immune function genes associated with recurrence-free survival in breast cancer patients.

Revisiting cancer immunoediting by understanding cancer immune complexity.

Comment on "Cutting edge: CD8+ T cell priming in the absence of NK cells leads to enhanced memory responses".

Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer.

Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.

An immunologic portrait of cancer.

Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity.

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma.

Favorable Outcomes in Patients with High Donor-Derived T Cell Count after in Vivo T Cell-Depleted Reduced-Intensity Allogeneic Stem Cell Transplantation.

Suppression of antigen-specific CD4(+) T cell activation by SRA/CD204 through reducing the immunostimulatory capability of antigen-presenting cell.